MUCOSOLVAN syrup for children should not be administered to patients with known hypersensitivity to ambroxol or other components of the product. In the case of rare congenital diseases that can lead to incompatibilities with some of the excipients (see Special Warnings), the use of the medicinal product is contraindicated.
MUCOSOLVAN syrup for children of 15 mg / 5 ml contains 5,25 g sorbitol per maximum recommended daily dose (15 ml). Patients with rare hereditary problems of fructose intolerance should not take this medicine. It is possible mild laxative effect. May cause gastrointestinal irritation and diarrhea. This medicinal product contains glycerol which is harmful in high doses. May cause gastrointestinal irritation and diarrhea. There are very rare reports of severe skin lesions, such as syndrome of Stevens-Johnson syndrome and Lyell, who are in transition from the application of mucolytic such as ambroxol. Usually, this is explained by the severity of the underlying disease or concomitant medication. If new lesions on the skin or mucous membranes should immediately seek medical advice and as a precautionary measure to stop treatment with ambroxol.
Administration of ambroxol together with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) leads to a higher concentration of the antibiotic in the bronchial secretions and saliva.
Not recommended for use ambroxol with medicines that suppress the cough.
Not reported significant adverse interactions with other medications.
Pregnancy and lactation
Ambroxol crosses the placental barrier. Animal studies do not indicate direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth and postnatal development.
Prolonged clinical observation with the use of the product during pregnancy after 28 weeks of gestation, showed no harmful effects on the fetus.
However, to be respected usual precautions regarding the use of medication during pregnancy. The use of MUCOSOLVAN, especially during the first three months of pregnancy is not recommended.
Ambroxol passes into breast milk. MUCOSOLVAN use is not recommended in breastfeeding women. However, do not expect adverse effects on the child.
In preclinical studies, that the active substance of MUCOSOLVAN syrup for children - ambroxol increases the secretion of the respiratory tract. Strengthens the production of pulmonary surfactant and stimulate ciliary activity (protective mechanisms of the lung). As a result of this increased flow of mucus and its transport. Strengthening of secretion and its transport facilitates expectoration and coughing.
The local anesthetic effect of ambroxol was observed on a rabbit eye model, which can be explained by the ability to block sodium channels.
These pharmacological properties are in accordance with further observations in clinical trials to study the effectiveness of treatment with ambroxol symptoms in the upper respiratory tract, leading to a sharp reduction in pain and related discomfort ear - nose - trachea through inhalation.
Further, recent clinical trials with lozenges containing ambroxol, demonstrated no significant effect on pain relief in an acute inflammation of the throat. Also, significantly reduces the redness of the sore throat.
5 ml syrup contains: 15 mg of ambroxol hydrochloride (ambroxol hydrochloride).
Excipients: hydroxyethylcellulose, sorbitol, glycerol, acesulfame potassium, a flavoring, benzoic acid, purified water.
Do not store above 30 ° C.
Keep out of reach of children.